First-line paclitaxel and cisplatin used sequentially or in combination in metastatic breast cancer: A phase II randomized study
Introduction: Breast cancer (BC) is the commonest cancer among females worldwide. Some patients present initially at advanced stages and more than 50% of them will develop metastasis (MBC) at some point. Compared to single agents, combination chemotherapy produces higher response rates (RR), longer...
Main Authors: | Mostafa M. Elserafi, Ahmed A. Zeeneldin, Ibrahim M. Abdelsalam, Hanan R. Nassar, Manar M. Moneer, Wafa H. Buhoush |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2018-03-01
|
Series: | Journal of the Egyptian National Cancer Institute |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1110036218300025 |
Similar Items
-
A randomized study of docetaxel plus cisplatin versus paclitaxel plus cisplatin in previously untreated advanced non-small cell lung cancer
by: Haiyong WANG, et al.
Published: (2008-02-01) -
A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer
by: Vaibhav Sahai, et al.
Published: (2019-09-01) -
Weekly chemotherapy with cisplatin and paclitaxel in advanced NSCLC: a phase II study
by: G. Buccheri, et al.
Published: (2016-02-01) -
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
by: Thomas Decker, et al.
Published: (2017-07-01) -
Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
by: Georgios Tsakonas, et al.
Published: (2020-10-01)